3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
Abstract Osimertinib sensitive and resistant NSCLC NCI-H1975 clones are used to model osimertinib acquired resistance in humanized and non-humanized mice and delineate potential resistance mechanisms. No new EGFR mutations or loss of the EGFR T790M mutation are found in resistant clones. Resistant t...
Main Authors: | Ismail M. Meraz, Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, RuPing Shao, Renduo Song, Feng Li, Yonathan Lissanu, Huiqin Chen, Min Jin Ha, Qi Wang, Jing Wang, Elizabeth Shpall, Sung Yun Jung, Franziska Haderk, Philippe Gui, Jonathan Wesley Riess, Victor Olivas, Trever G. Bivona, Jack A. Roth |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-05-01
|
Series: | Communications Biology |
Online Access: | https://doi.org/10.1038/s42003-023-04889-w |
Similar Items
-
Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
by: Ismail M. Meraz, et al.
Published: (2023-06-01) -
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
by: Ismail M Meraz, et al.
Published: (2025-02-01) -
TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
by: Ismail M. Meraz, et al.
Published: (2022-02-01) -
Phosphoinositides in the kidney
by: Leopoldo Staiano, et al.
Published: (2019-02-01) -
TAPO in first‐line osimertinib therapy and continuation of osimertinib
by: Chihiro Mimura, et al.
Published: (2023-02-01)